“As we prepare for rapid growth in our antibody therapeutics portfolio, I am delighted to welcome Yuwen to our Board of Directors, as well as Jiping and Dana to our global leadership team,” said declared
The backgrounds of leaders include:
Liu Yuwenis a leading advocate for the biotechnology, biopharma and medical technology industries, with over 20 years of experience as an entrepreneur, advisor and investor. For more than nine years, she was President and Chief Executive Officer, then General Manager, of Suzhou Industrial Park Biotech Development Co. Ltd.(BioBAY), transforming it into one of the fastest growing biotech clusters serving more than 400 start-ups, including BrightGene, Innovent and Qiagen ( suzhou), where she also served on the boards of directors. A fervent supporter of innovation, she was also a founding partner of BOHE Angel Fundone of the first angel funds in Chinafocusing on healthcare start-ups, which invest in biologics, drug discovery and diagnostics. She was also founding president of Investment of the BioVENTURE FundCommittee. Ms. Liupreviously been the first Chief Representative to set up the ChinaPerrigo operation. Earlier in her career, she held various quality and business development positions at Capsugel, a division of Warner-Lambert later acquired by Pfizer. Ms. LiuGraduated from China Pharmaceutical Universityholds a master’s degree in pharmacy and a master’s degree in management from Fudan Universityand the Norwegian School of Management BI. She is a licensed pharmacist. Jiping ZhaMD, Ph.D., licensed physician in the state of californiaand board certified in Anatomical Pathology, was named Executive Vice President of Clinical Development. Dr Zhais a physician scientist with over 20 years of experience in drug discovery and development with deep expertise in disease biology, translational sciences, biomarker discovery, precision medicine and clinical development. He has successfully led several large and small molecule programs, from IND stages to clinical trials. By leveraging its deep medical and scientific expertise as a scientific leader in Genentechand MedImmune for approximately seven years and three years, respectively, he played a key leadership role in the development and execution of several biomarker/companion diagnostic programs. before joining Adagene, Dr Zhaserved as Executive Director of Translational Sciences at NGM Biopharmaceuticals, where he led the clinical development of a new antibody drug program in solid tumors and oversaw translational strategies for its entire pipeline that spans oncology, metabolic and ophthalmology. He was vice president of cancer biology and senior vice president of drug discovery technologies at Crown Bioscience, acquired by Japanese company JSR Corporation. Dr Zhais the author of several patents and more than 40 publications in high-impact scientific journals, including Cell, Science and Nature. He got his MD from Shanghai Medical University, and Ph.D. in Microbiology and Immunology of University of Tennessee Health Sciences Center. Dr Zhahas previously held professorships and senior research positions at Harvard Medical Schooland the University of Texas Southwestern Medical Centerat dallas. Dana Hu Lowe, Ph.D., is the Vice President of Global Product Team Leadership, with over 20 years of experience in oncology drug discovery, pharmacology, translational research and clinical development, including project management and of strategic alliances. Previously, Dr. Hu-Lowe was Executive Director and Global Product Team Leader (GPTL) at Turning Point Therapeutics, where she was responsible for the early clinical development of enzolvantinib and TPX-0046. Previously, Dr. Hu-Lowe was the Senior Director of strategic allianceand program management Wellspring Biosciences Inc.where she managed both internal IND discovery and activation programs, as well as a strategic alliance with Janssen Pharmaceuticals. Dr. Hu-Lowe also worked at Pfizer Oncology for over 12 years, where she led cross-functional teams advancing programs from preclinical to clinical development. At Pfizer, Dr. Hu-Lowe directly contributed to new drug demand and weFDA approvals for axitinib (Inlyta™) and sunitinib (Sutent™), and she received the Career Achievement Award. She earned a degree in chemistry from Beijing Normal University, and a Ph.D. in the biochemistry of University of Mississippi. She completed her post-doctoral training at Scripps Research Instituteand the Burnham Cancer Center(now the Sanford Burnham Prebys Medical Discovery Institute).
Drs. Zha and Hu-Lowe have partnered to lead the company’s clinical development, taking over responsibilities from Dr.
Additionally, the CFO
For more information, please visit: https://investor.adagene.com. To follow
SAFE body® is a trademark registered in
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding potential clinical data implications for patients, as well as Adagene’s anticipated clinical progress and activities, clinical development, regulatory milestones and commercialization of its candidate products. Actual results may differ materially from those indicated in the forward-looking statements due to various important factors, including, but not limited to, Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results of its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by relevant regulatory authorities regarding the regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain intellectual property protection for its technology and medicines; Adagene’s reliance on third parties to carry out drug development, manufacturing and other services; Adagene’s limited operating history and its ability to obtain additional financing for its operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as the risks more fully discussed in the “Risk Factors” section in the documents filed by Adagene with the
Internal contact person:
2022 GlobeNewswire, Inc., source